Allakos Inc (NAS:ALLK)
$ 1.3 0.04 (3.17%) Market Cap: 112.57 Mil Enterprise Value: 59.75 Mil PE Ratio: 0 PB Ratio: 1.55 GF Score: 28/100

Allakos Inc Investor Day Transcript

Feb 15, 2022 / 01:15PM GMT
Release Date Price: $6.86 (+10.29%)
Operator

Greetings, and welcome to the Allakos Investor Day. (Operator Instructions) As a reminder, this conference is being recorded. I'll now turn the conference over to Mr. Robert Alexander, CEO.

Mr. Alexander, you may now begin your presentation.

Robert Alexander
Allakos Inc. - CEO & Director

All right. Thank you. Good morning, everyone, and thank you for joining the call.

Before we begin, a reminder that we will be making forward-looking statements, so please refer to our filings with the SEC. With me here today are Craig Paterson, our Chief Medical Officer; Baird Radford, our CFO; Brad Youngblood, our Head of Research; and Adam Tomasi, our President and COO.

As for the agenda, we -- following my introductory remarks, Craig will go through our KRYPTOS and ENIGMA studies. We'll then be joined by Dr. Evan Dellon, to give his perspective on the EGID space and specifically these 2 clinical studies. I will then go through the scientific rationale for our programs with lirentelimab and atopic derm and chronic spontaneous urticaria.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot